Buys | $3,374,588 | 4 | 6 |
Sells | $11,916,965 | 61 | 94 |
MOTT DAVID M | director | 4 | $3.37M | 0 | $0 | $3.37M |
Rodriguez Susan | Chief Commercial Officer | 0 | $0 | 1 | $52,357 | $-52,357 |
Renz Justin A | Chief Financial Officer | 0 | $0 | 4 | $125,650 | $-125,650 |
Blanks Robert | See Remarks | 0 | $0 | 4 | $317,022 | $-317,022 |
Rosenbaum David P. | Chief Development Officer | 0 | $0 | 11 | $1.37M | $-1.37M |
Williams Laura A | Chief Medical Officer | 0 | $0 | 6 | $1.51M | $-1.51M |
Felsch Robert Ora | See Remarks | 0 | $0 | 3 | $1.88M | $-1.88M |
RAAB MICHAEL | President & CEO | 0 | $0 | 25 | $2.92M | $-2.92M |
GRAMMER ELIZABETH A | See Remarks | 0 | $0 | 7 | $3.75M | $-3.75M |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing …
Over the last 12 months, insiders at Ardelyx, Inc. have bought $3.37M and sold $11.92M worth of Ardelyx, Inc. stock.
On average, over the past 5 years, insiders at Ardelyx, Inc. have bought $2.13M and sold $5.47M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MOTT DAVID M (director) — $3.37M.
The last purchase of 77,729 shares for transaction amount of $388,738 was made by MOTT DAVID M (director) on 2025‑02‑24.
2025-03-07 | Sale | RAAB MICHAEL | President & CEO | 41,668 0.0176% | $5.36 | $223,199 | +2.45% | |
2025-02-24 | MOTT DAVID M | director | 77,729 0.0322% | $5.00 | $388,738 | +3.70% | ||
2025-02-20 | Sale | RAAB MICHAEL | President & CEO | 22,964 0.0086% | $5.62 | $129,124 | -6.36% | |
2025-02-20 | Sale | Williams Laura A | Chief Medical Officer | 4,941 0.0018% | $5.62 | $27,783 | -6.36% | |
2025-02-20 | Sale | Renz Justin A | Chief Financial Officer | 5,171 0.0019% | $5.62 | $29,077 | -6.36% | |
2025-02-20 | Sale | GRAMMER ELIZABETH A | See Remarks | 4,291 0.0016% | $5.62 | $24,128 | -6.36% | |
2025-01-31 | Sale | RAAB MICHAEL | President & CEO | 41,666 0.0176% | $5.36 | $223,355 | +1.49% | |
2025-01-21 | MOTT DAVID M | director | 199,000 0.0854% | $4.99 | $992,672 | +10.95% | ||
2025-01-07 | Sale | RAAB MICHAEL | President & CEO | 41,666 0.0174% | $5.31 | $221,309 | +0.37% | |
2024-12-19 | MOTT DAVID M | director | 213,300 0.0889% | $4.67 | $996,580 | +14.29% | ||
2024-12-10 | Sale | RAAB MICHAEL | President & CEO | 25,000 0.0105% | $5.26 | $131,620 | +1.14% | |
2024-11-25 | Sale | RAAB MICHAEL | President & CEO | 25,000 0.0107% | $5.38 | $134,483 | +2.00% | |
2024-11-20 | Sale | RAAB MICHAEL | President & CEO | 31,980 0.0132% | $4.79 | $153,328 | +8.74% | |
2024-11-20 | Sale | Blanks Robert | See Remarks | 4,941 0.002% | $4.79 | $23,690 | +8.74% | |
2024-11-20 | Sale | Williams Laura A | Chief Medical Officer | 7,366 0.003% | $4.79 | $35,316 | +8.74% | |
2024-11-20 | Sale | Renz Justin A | Chief Financial Officer | 5,260 0.0022% | $4.79 | $25,219 | +8.74% | |
2024-11-20 | Sale | GRAMMER ELIZABETH A | See Remarks | 7,046 0.0029% | $4.79 | $33,782 | +8.74% | |
2024-11-20 | Sale | Rosenbaum David P. | Chief Development Officer | 7,184 0.003% | $4.79 | $34,444 | +8.74% | |
2024-11-13 | MOTT DAVID M | director | 215,868 0.0924% | $4.62 | $996,598 | +18.22% | ||
2024-11-11 | Sale | RAAB MICHAEL | President & CEO | 2,743 0.0012% | $4.90 | $13,441 | +8.69% |
MOTT DAVID M | director | 2015494 0.8456% | $10.92M | 12 | 0 | +19.65% |
RAAB MICHAEL | President & CEO | 1635138 0.686% | $8.86M | 1 | 56 | +248.1% |
Williams Laura A | Chief Medical Officer | 303804 0.1275% | $1.65M | 1 | 15 | +248.1% |
Renz Justin A | Chief Financial Officer | 285968 0.12% | $1.55M | 1 | 20 | +248.1% |
GRAMMER ELIZABETH A | See Remarks | 181043 0.076% | $981,253.06 | 2 | 41 | +117.06% |
$8,217,280 | 112 | 46.33% | $1.31B | |
$831,902,292 | 108 | 9.34% | $1.56B | |
$20,297,544 | 73 | 103.06% | $1.58B | |
$54,590,806 | 65 | 21.84% | $1.25B | |
Ardelyx, Inc. (ARDX) | $1,101,324,300 | 58 | 37.37% | $1.29B |
Increased Positions | 122 | +53.98% | 22M | +15.34% |
Decreased Positions | 98 | -43.36% | 13M | -9.01% |
New Positions | 47 | New | 8M | New |
Sold Out Positions | 36 | Sold Out | 3M | Sold Out |
Total Postitions | 250 | +10.62% | 151M | +6.33% |
Janus Henderson Group Plc | $130,719.00 | 10.25% | 24.39M | +3M | +13.28% | 2024-12-31 |
Blackrock, Inc. | $99,275.00 | 7.78% | 18.52M | +694,542 | +3.9% | 2024-12-31 |
Vanguard Group Inc | $76,984.00 | 6.04% | 14.36M | +767,111 | +5.64% | 2024-12-31 |
State Street Corp | $62,138.00 | 4.87% | 11.59M | -548,936 | -4.52% | 2024-12-31 |
Macquarie Group Ltd | $55,458.00 | 4.35% | 10.35M | +1M | +15.62% | 2024-12-31 |
Eventide Asset Management, Llc | $30,020.00 | 2.35% | 5.6M | -2M | -24.45% | 2024-12-31 |
Geode Capital Management, Llc | $29,532.00 | 2.32% | 5.51M | +21,988 | +0.4% | 2024-12-31 |
Millennium Management Llc | $15,884.00 | 1.25% | 2.96M | -1M | -26.13% | 2024-12-31 |
Citadel Advisors Llc | $13,350.00 | 1.05% | 2.49M | +281,685 | +12.75% | 2024-12-31 |
Morgan Stanley | $12,980.00 | 1.02% | 2.42M | -712,788 | -22.74% | 2024-12-31 |